BLRD Research Career Scientist Award Application

BLRD 研究职业科学家奖申请

• 批准号: 10593999
• 负责人: Michal A Olszewski
• 金额: --
• 依托单位: VETERANS HEALTH ADMINISTRATION
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-04-01 至 2027-03-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10593999
• 关键词: Acquired Immunodeficiency Syndrome; Acute Respiratory Distress Syndrome; Animal Model; Antibiotic Therapy; Antibody Therapy; Antifungal Agents; Area; Autoimmune Diseases; Award; Bioinformatics; Brain; COVID-19 pandemic; COVID-19 patient; COVID-19/ARDS; CXCR3 gene; Caliber; Cause of Death; Cerebrum; Chronic lung disease; Clinical Data; Clinical Research; Code; Collaborations; Communicable Diseases; Communities; Complement; Cryptococcosis; Cryptococcus; Cryptococcus neoformans; Death Domain; Dendritic Cells; Dendritic cell activation; Development; Disease; Drug resistance; Effectiveness; Epigenetic Process; Exhibits; Exposure to; Foundations; Funding; Future; Genes; Genetic Transcription; Goals; Grant; HIV; Healthcare; Host Defense; Host Defense Mechanism; Human; Hypersensitivity; Immune; Immune Evasion; Immune response; Immune system; Immunity; Immunocompetent; Immunocompromised Host; Immunologics; Immunologist; Immunology; Immunotherapeutic agent; Immunotherapy; Individual; Infection; Inflammation; Inflammatory; Integration Host Factors; Interleukin-10; Intervention; Knowledge; Location; Lung; Lung infections; Malignant Neoplasms; Mentors; Microbe; Modification; Molecular; Morbidity - disease rate; Mycoses; National Institute of Allergy and Infectious Disease; Organ Transplantation; Organism; Outcome; Pathogenesis; Pathologic; Pathology; Pathway interactions; Patients; Phenotype; Predisposition; Process; Productivity; Publications; Published Comment; Publishing; RIPK3 gene; Regimen; Research; Resistance development; Risk; Risk Factors; Role; SARS-CoV-2 infection; Science; Scientist; Services; Signal Pathway; Signal Transduction; Site; Source; Substance abuse problem; T cell response; T-Lymphocyte; TNF gene; Testing; Therapeutic; Toxic effect; Transplant Recipients; United States National Institutes of Health; Validation; Veterans; Virulence Factors; Work; antimicrobial; career; chronic infection; cytokine; design; editorial; experience; fungus; global health; high risk; human data; immunomodulatory therapies; immunopathology; immunoregulation; interest; microbial; microorganism interaction; military service; monocyte; mortality; mouse model; mutant; neglect; neutrophil; novel therapeutics; novel vaccines; pathogen; patient population; pre-clinical; prevent; programs; receptor; response; risk stratification; scavenger receptor; stem; therapeutic target; translational study; tumor; vaccine strategy

Dr. Olszewski is an immunologist with over 25 years of experience in studies of inflammatory/infectious diseases in the lungs, CNS and at the systemic level with over 20 years of research at the Ann Arbor VAHS. Overall career goal is to expand the understanding of host pathogen interactions, specifically the effect of microbe- and host-derived signals on the fate of the immune response. Understanding of these interactions will create a foundation for the development of safe and effective immunomodulatory therapies that will greatly enhance the effectiveness of antimicrobial therapeutics in persistent infections. Nominee’s lab has specialized in animal modeling and translational studies, applying these principles to a broader range of diseases as shown by more recent clinical data. His studies have mostly focused on host pathogen interactions between invasive fungus C. neoformans and the mammalian immune system. The studies of invasive fungal infections are of specific interest to the VA, because of the higher than average rate of immunocompromised patients among veterans and increased risk of exposure to various endemic and environmental fungi due to locations and conditions of military service that favor fungal exposures. Unfortunately, the invasive fungal infections have unacceptably high mortality rates, due to limited effectiveness of antifungal drugs, toxicity, and the high potential of fungal organisms to develop resistance to these drugs. Thus, it is crucial to understand the effects of immunomodulation on fungal disease from the perspective of the natural mechanisms of host defenses, mechanisms of immune evasion exhibited by fungi, and to explore pre-clinical approaches of immunomodulatory therapies. The long-standing support of VA BLR&D was one of the crucial factors that allowed our group to establish itself among leaders in cryptococcal and fungal immunology. Additional areas of work involve clinical studies looking into pathogenesis od ARDS in COVID19 patients and infections of GI track. The VA RCS Award will allow the nominee to continue his productive research career, successful mentoring of new scientists and to provide service to the research community at the VA and beyond.

Olszewski博士是一位免疫学家，在研究方面拥有超过25年的经验 肺部，中枢神经系统和全身性疾病的炎症/传染病在20多年以上 Ann Arbor Vahs的研究。总体职业目标是扩展对主持人的理解 病原体相互作用，特别是微生物和宿主信号对命运的影响 免疫反应。对这些互动的理解将为 开发安全有效的免疫调节疗法，将大大增强 抗菌治疗在持续感染中的有效性。提名的实验室有 专门从事动物建模和翻译研究，将这些原理应用于更广泛的 疾病范围如最近的临床数据所示。 他的研究主要集中在侵入性真菌之间的宿主病原体相互作用上。 Neoformans和哺乳动物免疫系统。侵入性真菌感染的研究是 由于免疫功能低下的速度高于平均水平，因此具有特定的感兴趣 退伍军人中的患者以及暴露于各种内在和环境的风险 真菌由于征收真菌暴露的位置和兵役状况而引起的。 不幸的是，由于 抗真菌药物，毒性和真菌生物的高潜力有限 对这些药物的发展耐药性。这是至关重要的 从宿主的自然机制的角度来对真菌疾病的免疫调节 防御，真菌暴露的免疫进化机制，并探索临床前 免疫调节疗法的方法。 VA Blr＆d的长期支持是一个 使我们小组在隐球菌领导者中建立自己的关键因素 真菌免疫学。其他工作领域涉及发病机理的临床研究 CoVID19患者和GI轨迹感染的OD ARD。 VA RCS奖将允许 提名人继续他的生产研究职业，新科学家的成功心理 为VA及其他地区的研究社区提供服务。